EDN1 and ovarian carcinoma: In this regard, it has been reported that macitentan, thanks to its ability to simultaneously interfere the ETAR-driven signalling that support cancer cell activity and the ETBR-mediated route strongly active in stromal cells, may potentiate PARPi effects, when administered in combinatorial regimen in breast and ovarian cancer cells highly expressing the ET-1/ET-1R axis [14].